Literature DB >> 1990015

Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract.

T Kuninaka1, Y Senga, H Senga, M Weiner.   

Abstract

The effect of calf blood extract (Solcoseryl, SS) on mitochondrial oxidative function in various states was studied polarographically in vitro. 1) Mitochondrial respiration in all 4 conventional study states (Estabrook, 1967) was enhanced by the addition of SS, including states 1 and 2 (endogenous substrates only). 2) The effect of SS on mitochondrial oxygen consumption was concentration dependent, while ADP/O ratio remained constant. The effect of added respiratory substrates varied with the particular substrate at optimally active concentrations. With suboptimal substrate levels, ADP/O ratios were concentration dependent, in contrast to the SS effect. Under oligomycin ATPase inhibition, SS was no longer active, in contrast to DNP, which remained active. 3) In states 3 (added ADP) and 4 (ADP exhausted), oxygen consumption and oxidative phosphorylation were enhanced by SS in the presence or absence of citrate, glutamate, pyruvate, lactate, or ascorbate. However, in the presence of succinate, SS had no effect. 4) ADP/O ratio was decreased by SS in the presence of added substrate, suggesting that SS activation of H(+)-ATPase enhances ATP hydrolysis as well as oxidative phosphorylation and ATP synthesis. 5) The enhancing effect of SS on mitochondrial function is due to hydrophilic components of SS. The lipidic components obtained by Folch fraction of SS have no effect. It is concluded that the effects of SS respiratory substrates and uncouplers on mitochondrial function are essentially different. SS enhances both ATP synthesis and oxygen consumption by mitochondria.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1990015     DOI: 10.1002/jcp.1041460119

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

Review 1.  Actovegin®: a biological drug for more than 5 decades.

Authors:  Florian Buchmayer; Johannes Pleiner; Martin W Elmlinger; Gereon Lauer; Gerfried Nell; Harald H Sitte
Journal:  Wien Med Wochenschr       Date:  2011-02

2.  Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia.

Authors:  Sigal Meilin; Fausto Machicao; Martin Elmlinger
Journal:  J Cell Mol Med       Date:  2014-05-06       Impact factor: 5.310

3.  Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.

Authors:  Dan Ziegler; Lusine Movsesyan; Boris Mankovsky; Irina Gurieva; Zhangentkhan Abylaiuly; Igor Strokov
Journal:  Diabetes Care       Date:  2009-05-26       Impact factor: 17.152

4.  A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design.

Authors:  Alla Guekht; Ingmar Skoog; Amos D Korczyn; Vladimir Zakharov; Martin Eeg; Ulf Vigonius
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2013-12-14

5.  Expression of vascular endothelial growth factor and basic fibroblast growth factor in acute rejection reaction following rat orthotopic liver transplantation.

Authors:  Changsong Zhang; Guangshun Yang; Dewen Lu; Yang Ling; Guihua Chen; Tianbao Zhou
Journal:  Exp Ther Med       Date:  2014-06-11       Impact factor: 2.447

6.  ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.

Authors:  Alla Guekht; Ingmar Skoog; Sally Edmundson; Vladimir Zakharov; Amos D Korczyn
Journal:  Stroke       Date:  2017-05       Impact factor: 7.914

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.